Medical services mergers and acquisitions Xiaoyangchun pressed the pause key the first half of the capital to the hospital target gathering.

The merger was undoubtedly one of the hottest words in the healthcare sector in 2019, but a sudden outbreak briefly interrupted the wave.
the domestic healthcare merger market since 2020 is a little dull.
, however, the market appears to be starting to pick up as the situation improves.
last week, Beijing's Mei Zhongyi and North Third Ring Women's and Children's Hospital (formerly Baodao Maternity Hospital) opened, and the merger of Mei Zhongyi and Medical to Baodao Hospital came to an end.
deal, which began in 2019, was largely finalized in the first half of 2020, but the new hospital has been slow to open due to factors such as the outbreak.
not only U.S.-China Yi and China, PwC said in its latest research report that although the pace of the market in the first half of 2020 was affected in the short term, but in the long run the industry is still favored by the market in the long run.
01. Mergers and acquisitions of Xiaoyangchun 2019 domestic health care industry mergers and acquisitions integration presents a blooming Yangchun scene, whether the industry's leading enterprises or small and beautiful new companies have been active in the merger and acquisition market.
2019, China's healthcare services market completed a total of 160 domestic and foreign mergers and acquisitions, amounting to about 60.4 billion yuan, the largest total transaction size since 2013.
, especially from the second half of 2019, the market, driven by the national policy environment, pulled the momentum of the same period in the first half of the year, and the amount of transactions increased significantly.
According to Hao Yue Capital, the total number of mergers and acquisitions in the healthcare sector increased by 2.2 times in 2019, with the average transaction value increased by 1.9 times, including five transactions in 2019 in which more than RMB 1 billion was 1 billion yuan (two of which exceeded 5 billion).
In July 19th, Xinfeng Tiantian acquired the domestic private high-end medical institution leader Harmony Family, which achieved a U.S. stock shell listing, with a valuation of about $1.44 billion, and the acquisition became the largest transaction in the medical services industry in 2019.
addition, Ali's stake in American Health, Fangyuan Capital and Chunhua Capital's stake in the people's big pharmacy and other transactions amounted to more than 4 billion yuan.
To the wave of mergers and acquisitions that began in 2019, Mei Zhongyi and founder and CEO Hu Lan said that the active merger is conducive to promoting the industry reshuffle, small, scattered, chaotic institutions will gradually withdraw from the market, with doctors, patients, capital and other resources concentrated on the head, the future market will appear more medical management, operational capacity of medical groups.
2020, negotiations and efforts to invest in mergers and acquisitions under the impact of the outbreak have been limited to varying degrees.
the first half of 2020, there were 71 financing mergers and acquisitions in China's healthcare services market, with a turnover of about 10 billion yuan, according to PwC Research.
year-on-year decline was more severe than in the same period last year, with a 30 per cent drop in the number of transactions and a 50 per cent drop in the value of transactions.
investment boom has briefly subsided.
number of large mergers and acquisitions in the healthcare sector also fell in the first half of 2020 compared with the same period in 2019.
only two of the deals announced were worth more than Rmb1bn, with the average deal reduced to Rmb210m.
the pace of investment stalled last year, there were new faces of more strategic investment in the healthcare sector in the first half of the year.
strategic investors have focused on and dominated the healthcare sector in 2019, contributing 70 percent of domestic healthcare sector mergers and acquisitions.
the health care industry's counter-cyclicality has become more prominent in the face of the epidemic, more investors in the non-medical health industry are beginning to lay out the healthcare industry in the hope of finding new business growth points through cross-border transformation.
the first half of 2020, led by risk capital, investors in the non-health care industry have further increased in the amount of transactions and the number of transactions.
in the sub-sector, the first half of the capital to hospitals and institutions of old-age institutions gathered, last year by the capital concerns of the transactions of the specialized hospital sector, the first half of the transaction is still active, the overall size of the same period last year.
Yihua Health, Sanbo Brain, Mei Zhongjia and other financing transactions accounted for more than half of the total medical and health services transactions in the first half of the year.
02. It is not only mergers and acquisitions for large-scale, high-tech head enterprises in the sub-sector, mergers and acquisitions can enhance their own strength and thus achieve rapid expansion of scale and market.
, the leading ophthalmology company in China, has been on its own path to mergers and acquisitions since 2014, keeping its revenue growth at more than 20% for a decade.
rapid expansion, Eyre Ophthalmology soared from a market capitalisation of less than $7bn when it went public in 2009 to $200bn today.
on the other hand, mergers and acquisitions also provide an important means for leading medical institutions in the segment to expand their business extension.
through mergers and acquisitions and their own business in the geographical, specialized or industrial chain has strong synergy of the target can achieve horizontal expansion category and vertical and downstream integration.
Speaking about why Baodao Hospital should be acquired, Mr Hu said Baodao Hospital was chosen on the one hand because it was in line with the company's strategic intentions and partly because of the assisted reproductive licences it had, "we are building every node in the entire industry chain."
" as the leading domestic private medical institutions on behalf of the United States and China yi and mainly for China's high-end families to provide obstetrics, gynecology, pediatrics, reproductive health, post-natal rehabilitation, comprehensive outpatient and medical services and other medical services.
as of 2020, Mei-China Yi and Medical will have a total of 7 women's and children's hospitals, 1 general out-patient clinic and 3 monthly sub-centers in beijing, Tianjin, Yangtze River Delta and Pearl River Delta regions.
also complemented the layout of the reproductive sector in the Beijing-Tianjin region through the acquisition of Mei Zhongyi and the possession of an assisted reproductive license held by Baodao Hospital.
because of high regulation and high barriers to access in the area of reproductive health, "licences are a relatively scarce resource".
the U.S.-China and its layout in the field of assisted reproduction will not have any meaning for its future.
"Capital is very concerned about the demand for assisted reproduction, and capital is more favourable to institutions with assisted reproductive licenses than ordinary maternity hospitals, " the Beijing Business Daily reported, citing private hospital managers.
" 2019 by Jinxin Medical Group's assisted reproductive business split Jinxin Reproductive successfully landed in Hong Kong shares, the market value of HK$24 billion on the same day.
For the U.S.-China Yihe listing plan, Hu Lan said that the current strategic layout of the hospital business has been basically mature, U.S.-China Yihe does not exclude listing, believe that the capital market can help the future development, and has begun to assess the listing, but there is no specific timetable.
in a research paper, the 2019 merger and acquisition trend shows that the strategic value of model innovation is gradually emerging in the healthcare industry, which may become a new orientation for future investment in medical services.
.